Yousef, H. (2020). A Randomized-Trial Study of Corneal Collagen Cross-Linking (CXL) in Progressive-Keratoconus (PK). The Egyptian Journal of Hospital Medicine, 81(6), 2179-2183. doi: 10.21608/ejhm.2020.127965
Hassan Shamselden Yousef. "A Randomized-Trial Study of Corneal Collagen Cross-Linking (CXL) in Progressive-Keratoconus (PK)". The Egyptian Journal of Hospital Medicine, 81, 6, 2020, 2179-2183. doi: 10.21608/ejhm.2020.127965
Yousef, H. (2020). 'A Randomized-Trial Study of Corneal Collagen Cross-Linking (CXL) in Progressive-Keratoconus (PK)', The Egyptian Journal of Hospital Medicine, 81(6), pp. 2179-2183. doi: 10.21608/ejhm.2020.127965
Yousef, H. A Randomized-Trial Study of Corneal Collagen Cross-Linking (CXL) in Progressive-Keratoconus (PK). The Egyptian Journal of Hospital Medicine, 2020; 81(6): 2179-2183. doi: 10.21608/ejhm.2020.127965
A Randomized-Trial Study of Corneal Collagen Cross-Linking (CXL) in Progressive-Keratoconus (PK)
Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Assiut, Egypt
Abstract
Background: Keratoconus is a frequent, familiar, bilateral, non inflammatory, and gradually progressive corneal ectasia, which leads to corneal protrusion, irregular astigmatism, and decrease vision. Currently, the corneal cross-linking (CXL) treatment could attain vision improvement. Aim: To investigate the topographic, refractive, and clinical-out-comes after six months CXL in gradually progressing keratoconic eyes. Patients & Methods: A follow-up, randomized, controlled-trial study was used. In this study, 30eyes with progressive- keratoconus (PK) were recruited in the study. Cross-linking was done and achieved by a solution of 0.1% riboflavin mixture with 20% dextran for 15minutes before and during 30minutes time-period of ultraviolet A (UV-A) irradiation (3Mw\cm2). The obtained data were analysed using IBM SPSS software. Results: Statistically significant improvements were noticed in Sim k (at 6months), Kmin (at 6months), spherical power (at 6momths), cylinder power (at 6momths), spherical equivalent [SE] (at 6months), uncorrected visual acuity (UCVA) (at 6months) and best corrected visual acuity [BCVA] (at 6months) in trial group (15patients) when compared with the controls. Conclusions: At 6months, hopeful, promising improvements were reported in Kmax, UCVA, and BCVA. So, long term studies are requested to survey the efficiency of CXL as well as the safety of the repeated procedures.